EGFR and neoplasm: Preclinical evidence has supported a radiosensitizing role for EGFR inhibition (193) and indeed, the addition of cetuximab to RT in patients with head and neck squamous cell cancer was shown to improve tumor control and overall survival compared with radiation alone (189).